Improving Hypertension Detection and Control Through a Hypertension Certification Program Based Upon the Hypertension Canada Guidelines

Not Applicable

Completed

• Conditions: Hypertension

• Registration Number: NCT03965104
• Lead Sponsor: University of Alberta

Brief Summary

This study will assess the impact of a hypertension management certification program for community pharmacists on the blood pressure control of patients managed by the pharmacists enrolled. The investigators will compare the systolic blood pressure of patients identified to have hypertension in the community that are followed by pharmacists who have undergone the certification course, and compare their blood pressure outcomes to subjects managed by pharmacists who have not yet received the training.

Detailed Description

Hypertension Canada proposes the first "Hypertension Canada Professional Certification Program"(HC-PCP), specifically designed for Alberta pharmacists, to provide care and support to those at risk for or living with hypertension. Through this program, the investigators hope to help with prevention of the costly and chronic conditions to which hypertension often leads, like kidney failure, stroke, and heart disease.

The HC-PCP aims to provide training to pharmacists in the screening, prevention, and management of hypertension. It has been identified that the development and implementation of this certification program provides a unique opportunity to evaluate the impact of such a program on blood pressure reduction.

The investigators are aiming to assess the impact of pharmacist management on blood pressure control in patients with hypertension.

The development of the HC-PCP and the evaluation of its impact will occur in 2 phases. Phase 1 involves the development and implementation of the educational portion of the certification program. Phase 2 involves conducting a 1 year long study to assess the impact of the HC-PCP on blood pressure in patients with poorly controlled hypertension. This will be launched in pharmacies in Alberta.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2019-05-23
• Study First Submitted QC: 2019-05-23
• Study First Posted: 2019-05-28
• Study Start: 2020-09-15
• Primary Completion: 2022-01-30
• Study Completion: 2022-01-30
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-03
• Last Update Posted: 2023-01-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 890

Inclusion Criteria

• Patients with poorly controlled blood pressure (>140/90mmHg or >130/80mmHg if they have diabetes).

Read More

Exclusion Criteria

• Unwilling to sign the consent form.
• Unwilling to participate in follow up visits.
• Current hypertension urgency or emergency (SBP > 180mmHg or DBP > 120mmHg).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
The difference in change in systolic blood pressure between Intervention and Control patients.	From baseline to 3 month follow-up, and up to one year	To detect a 7 millimeters of mercury (mmHg) or greater difference in systolic blood pressure.

Secondary Outcome Measures

Name	Time	Method
Consultant Satisfaction Questionnaire	6 months following follow up	patient satisfaction

Trial Locations

Locations (1)

University of Alberta; 🇨🇦 Edmonton, Alberta, Canada